Bluesky Explorer

#APLMW

Latest posts tagged with #APLMW on Bluesky

Trending

#MJF Tribute #Javier Bardem #WBC #Marty Supreme #Jessie Buckley #Andrade #Academy Awards #MBJ #Autumn Durald Arkapaw #Wallace #MJF Tribute #Javier Bardem #WBC #Marty Supreme #Jessie Buckley #Andrade #Academy Awards #MBJ #Autumn Durald Arkapaw #Wallace

Posts tagged #APLMW

@stocktitan.net

2 months ago

Preview

Apollomics Reports First Half 2025 Financial Results Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced

#APLM #APLMW Apollomics Reports First Half 2025 Financial Results

www.stocktitan.net/news/APLM/apollomics-rep...

0 0 0 0

@stocktitan.net

3 months ago

Preview

Apollomics Announces Settlement of Cayman Litigation Apollomics (Nasdaq: APLM) entered a settlement resolving Cayman Islands litigation with TWVC related to preferred‑share redemptions before its 2023 merger with Maxpro Capital Acquisition Corporation. The company agreed to pay US$5.0 million in cash in several installments over two years plus approximately US$879,757.78 in legal expenses.TWVC will withdraw all claims and the parties are submitting the Settlement Agreement for court approval to conclude the proceedings. The original damages claimed by TWVC were approximately US$40 million, as disclosed in Apollomics' April 2025 Form 20‑F.

#APLM #APLMW Apollomics Announces Settlement of Cayman Litigation

www.stocktitan.net/news/APLM/apollomics-ann...

0 0 0 0

@stocktitan.net

5 months ago

Preview

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation Apollomics (Nasdaq: APLM) said Nasdaq notified the company on October 14, 2025 that the Listing Qualifications Staff determined Apollomics is in compliance with Nasdaq continued listing requirements.As a result, Nasdaq cancelled the previously scheduled appeal hearing and Apollomics securities will remain listed and continue to trade on The Nasdaq Stock Market. The company had earlier filed an application to appeal a delisting notification and requested a hearing before a Nasdaq Hearings Panel.

#APLM #APLMW Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

www.stocktitan.net/news/APLM/apollomics-ann...

0 0 0 0

@stocktitan.net

11 months ago

Preview

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress Apollomics (NASDAQ: APLM) reported its full year 2024 financial results and clinical updates. The company secured a strategic collaboration with LaunXP for vebreltinib development, bringing in a $10 million upfront payment. Key clinical highlights include a 43% objective response rate in non-CNS MET fusion solid tumors and 30% response rate in high MET gene copy number patients.Financial results show cash position of $9.8 million as of December 31, 2024, compared to $37.8 million in 2023. R&D expenses decreased to $24.6 million from $34.2 million, while administrative expenses reduced to $17.8 million from $20.6 million. Net loss for 2024 was $(53.9) million or $(52.80) per share, improved from $(172.6) million loss in 2023.The company implemented strategic expense reductions and expects current cash, combined with the LaunXP payment, to fund operations into Q1 2026.

#APLM #APLMW Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

www.stocktitan.net/news/APLM/apollomics-rep...

0 0 0 0

@stocktitan.net

11 months ago

Preview

$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia Strategic partnership brings $10M upfront plus $50M in milestones for innovative lung cancer combination therapy. Expansion targets key Asian markets. Full analysis inside.

#APLM #APLMW Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

www.stocktitan.net/news/APLM/apollomics-and...

0 0 0 0

@stocktitan.net

1 year ago

Preview

Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated Key cancer drug uproleselan falls short in Phase 3 trial for acute myeloid leukemia, showing reduced survival rates compared to standard therapy, leading to program termination.

#APLM #APLMW Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

www.stocktitan.net/news/APLM/apollomics-ann...

0 0 0 0

@stocktitan.net

1 year ago

#APLM #APLMW Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

www.stocktitan.net/news/APLM/apollomics-ann...

0 0 0 0